NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

A new class of antibodies targeting a previously untargeted part of the malaria parasite shows promise for new prevention methods. The most potent antibody, MAD21-101, protected against P. falciparum in mice, binding to a conserved epitope outside the central repeat region of PfCSP. This discovery could lead to new vaccines and antibodies, potentially preventing malaria in at-risk infants and complementing existing vaccines.

NIH researchers discovered novel antibodies targeting a new malaria parasite region, offering innovative prevention strategies. These antibodies, effective in animal models, bind to unexplored parasite areas, promising advancements in malaria interventions and vaccine development.

The U.S. HHS announced $306 million for H5N1 Avian Flu response, focusing on surveillance, research, and preparedness. Funds will support disease monitoring, enhance biosurveillance, and develop medical countermeasures. The initiative aims to prevent transmission among humans and animals, ensuring food safety and advancing vaccine and diagnostic development.

NIH researchers discovered a novel class of antibodies targeting a new malaria parasite epitope, pGlu-CSP, offering potential for new prevention methods. This breakthrough could lead to effective vaccines and antibodies, especially beneficial for at-risk infants, without interfering with current vaccines.

NIH researchers discovered a novel class of antibodies targeting a new site on the malaria parasite, Plasmodium falciparum, offering potential for new prevention methods. The most potent antibody, MAD21-101, binds to a conserved epitope outside current vaccine targets, showing promise in animal models for malaria protection.

NIH researchers discovered a new class of antibodies targeting a unique part of the malaria parasite, offering potential for novel prevention methods. The most effective antibody, MAD21-101, protected against malaria in mice by binding to a conserved epitope, pGlu-CSP, not targeted by current vaccines. This breakthrough could lead to new malaria prevention strategies and vaccines.

Japan approved SIGA Technologies' TEPOXX, the first antiviral for orthopoxviruses, targeting smallpox, mpox, cowpox, and vaccination complications. Approved based on 15 trials showing safety and efficacy, TEPOXX inhibits the VP37 protein, slowing virus spread. Despite a trial in Congo not meeting its primary endpoint, SIGA's stock rose.

A study found RSV vaccine responses weaker in immunocompromised older adults, with 61% seroconverting. Adjuvanted vaccines showed better neutralization, suggesting potential for enhanced doses in this group.

NIH officials state H5N1 poses a low public risk, emphasizing vigilance, collaboration, surveillance, medical countermeasures, and preventive measures to control its spread and evolution.